Sales of Medicube’s capsule cream to resume; small amounts of banned dye detected in only 2 batches
The banned dye was found in samples sold by local beauty product retailer Venus.
Singapore's skincare brand Medicube will resume selling its PDRN Pink Collagen Capsule Cream after only two batches of samples tested positive for a banned cancer-linked substance. The Health Sciences Authority (HSA) announced on August 28 that minute amounts of Sudan IV, a red dye linked to carcinogenic effects, were detected in samples sold by Venus Beauty, a local beauty retailer.
The dye was not found in samples from two other companies, Rirora International and Medicube's Singapore subsidiary APR SG. HSA instructed a recall for the affected batches, numbered 2E122I, 2E117I, and 2E191G, 2E193G. Despite the minute quantities, consumers are advised not to use the affected products and to contact sellers with concerns about refunds.
HSA has requested all batch tests be conducted by an accredited Singapore lab before resale. Sudan Red dyes are prohibited in cosmetic products in Singapore, and companies found supplying such products may face penalties, including imprisonment and fines. Medicube's parent company APR Corp stated that independent testing in South Korea, China, and Taiwan also found no Sudan Red in their samples.
The company emphasized that customers should only purchase Medicube products through official channels to ensure authenticity, storage, and quality.
Written by urgent.news from Straits Times's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
